1. Home
  2. DMF vs THRD Comparison

DMF vs THRD Comparison

Compare DMF & THRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DMF
  • THRD
  • Stock Information
  • Founded
  • DMF 1988
  • THRD 2019
  • Country
  • DMF United States
  • THRD United States
  • Employees
  • DMF N/A
  • THRD N/A
  • Industry
  • DMF Finance/Investors Services
  • THRD Biotechnology: Pharmaceutical Preparations
  • Sector
  • DMF Finance
  • THRD Health Care
  • Exchange
  • DMF Nasdaq
  • THRD Nasdaq
  • Market Cap
  • DMF 152.2M
  • THRD 157.7M
  • IPO Year
  • DMF N/A
  • THRD 2022
  • Fundamental
  • Price
  • DMF $7.18
  • THRD $3.50
  • Analyst Decision
  • DMF
  • THRD Hold
  • Analyst Count
  • DMF 0
  • THRD 3
  • Target Price
  • DMF N/A
  • THRD $5.00
  • AVG Volume (30 Days)
  • DMF 60.7K
  • THRD 339.6K
  • Earning Date
  • DMF 01-01-0001
  • THRD 03-27-2025
  • Dividend Yield
  • DMF 2.66%
  • THRD N/A
  • EPS Growth
  • DMF N/A
  • THRD N/A
  • EPS
  • DMF 0.15
  • THRD N/A
  • Revenue
  • DMF N/A
  • THRD N/A
  • Revenue This Year
  • DMF N/A
  • THRD N/A
  • Revenue Next Year
  • DMF N/A
  • THRD N/A
  • P/E Ratio
  • DMF $45.13
  • THRD N/A
  • Revenue Growth
  • DMF N/A
  • THRD N/A
  • 52 Week Low
  • DMF $5.37
  • THRD $3.18
  • 52 Week High
  • DMF $6.79
  • THRD $16.94
  • Technical
  • Relative Strength Index (RSI)
  • DMF 46.06
  • THRD 36.34
  • Support Level
  • DMF $7.13
  • THRD $3.41
  • Resistance Level
  • DMF $7.29
  • THRD $3.68
  • Average True Range (ATR)
  • DMF 0.07
  • THRD 0.14
  • MACD
  • DMF -0.02
  • THRD 0.09
  • Stochastic Oscillator
  • DMF 17.24
  • THRD 41.91

About DMF BNY Mellon Municipal Income Inc.

BNY Mellon Municipal Income, Inc. is a non-diversified closed-end management investment company. Its investment objective is to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital. The fund invests in municipal obligations that are rated investment grade and have maturities of less than one year. The company targets to invest in the sector such as education, pre-refunded muni, utility, transportation, healthcare, special tax, state/territory general obligations, industry revenue, and pollution control.

About THRD Third Harmonic Bio Inc.

Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.

Share on Social Networks: